secwatch.observer — SEC 8-K summary
======================================

Issuer:     Royalty Pharma plc (RPRX)
CIK:        0001802768
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001193125-25-173988
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Royalty Pharma Q2 Portfolio Receipts +20% to $727M; raises FY 2025 guidance
---------------------------------------------------------------------------

- Portfolio Receipts $727M (+20% YoY); Royalty Receipts $672M (+11%), driven by Voranigo, Trelegy, Evrysdi, Tremfya.
- Raised FY 2025 Portfolio Receipts guidance to $3.05B-$3.15B (was $2.975B-$3.125B).
- Capital deployment of $595M in Q2; $1B in share repurchases in H1 2025 (31M shares).
- Completed acquisition of external manager RP Management in May, making Royalty Pharma an integrated company.
- Entered up to $2B funding arrangement with Revolution Medicines, including $1.25B synthetic royalty on daraxonrasib.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802768/000119312525173988/0001193125-25-173988-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802768/000119312525173988/d90343d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-173988

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer